ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Akashi Therapeutics has halted a clinical trial of the Duchenne muscular dystrophy treatment HT-100 after a patient taking the highest dose of the drug experienced life-threatening health issues. The company noted that no other serious safety issues have been observed with HT-100, an anti-fibrosis agent, and it hopes to restart the study once it has investigated the cause of the patient’s decline. Separately, FDA has put a study of Medivation’s pidilizumab on partial clinical hold after the biotech discovered the cancer drug’s mechanism of action is unclear. Previously, pidilizumab was considered a PD-1 inhibitor, the same class as successful cancer treatments from Merck & Co. and Bristol-Myers Squibb.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X